Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Gérard Zalcman MD, PhD

Gérard Zalcman MD, PhD

Professor of Pulmonology, Université Paris Cité; Chair, Thoracic Oncology Department, Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Medical Director, Institute of Cancer AP-HP.Nord, Paris, France

Gérard Zalcman, MD, PhD, is full professor of Pulmonology at Université Paris Cité, Paris, France and chairs the Thoracic Oncology Department of Bichat Hospital, at Assistance Publique-Hôpitaux de Paris. He serves as medical Director of the Institute of Cancer AP-HP.Nord. He is the senior author of the three randomized trials pubished in Lancet and Lancet Oncol journals, which established the current standard treatments for mesothelioma, either pemetrexed-based chemotherapy plus bevacizumab, or the immunotherapy combo Nivolumab+ipilimumab.